Accelagen is a Gene-to-Protein company that specializes in providing high-quality services and products for protein expression and purification. The company employs a range of advanced technologies, including the Baculovirus Expression Vector System (BEVS), E. coli expression systems, and mammalian expression systems, to produce recombinant proteins. These technologies enable Accelagen to deliver premium quality proteins that are essential for various applications, such as drug discovery, high-throughput screening, and pre-clinical studies. The integration of Wave Bioreactors and AKTA chromatography systems further enhances their protein purification processes, ensuring superior quality and efficiency.

The expertise of Accelagen's scientists extends to the production of a diverse array of therapeutic proteins, including antibodies, GPCRs, kinases, and nuclear receptors. Their comprehensive gene-to-protein platform is designed to accelerate the transition from gene to protein, providing clients with timely and cost-effective solutions. Accelagen's commitment to technical excellence and quality communication has established a strong track record of successful project completion, making them a reliable partner in the field of molecular biology and protein research.

United States

The company providesmolecular biology services includingproduction of antibodies, GPCRs, kinases, nuclear receptors, and many other classes of drug targets and therapeutic proteins

Accelagen

Company Details